Medicinal composition containing lenvatinib, and preparation method thereof
A technology of lenvatinib and composition, which is applied in the field of pharmaceutical composition containing lenvatinib and its preparation, and can solve the problems of slow release and low dissolution
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0027] The influence of embodiment 1 anhydrous calcium hydrogen phosphate on the dissolution rate of lenvatinib mesylate capsule
[0028] This embodiment investigates and illustrates the influence of anhydrous calcium hydrogen phosphate on the dissolution rate of lenvatinib mesylate capsules.
[0029] Lenvatinib mesylate capsules were prepared according to the prescription shown in Table 1 below, and the dissolution rate was measured, and the results are shown in Table 2.
[0030] Preparation method: Put the prescribed amount of lenvatinib mesylate, anhydrous calcium hydrogen phosphate, filler, and disintegrating agent into a fluidized bed and mix evenly, use 95% ethanol for granulation, and dry until the water content is less than 2%. Discharge, granulate the dried granules, add lubricant and mix evenly, and then fill into capsules.
[0031] Table 1 Components and dosages of prescriptions 1 to 6
[0032]
[0033] Table 2 Dissolution test results of prescriptions 1 to 6 ...
Embodiment 2
[0036] Embodiment 2 Anhydrous calcium hydrogen phosphate particle size is on the influence of capsule dissolution rate and uniformity
[0037] This example examines and illustrates the influence of anhydrous calcium hydrogen phosphate particle size on capsule dissolution rate and particle uniformity.
[0038] Lenvatinib mesylate capsules were prepared according to the prescription shown in Table 3 below. Wherein the particle diameter of anhydrous calcium hydrogen phosphate in prescription 7,10 is about 80 orders (equivalent to D 90 ≤180μm), the particle size of anhydrous calcium hydrogen phosphate in prescriptions 8, 9, 11, and 12 is about 200 mesh (equivalent to D 90 ≤75μm).
[0039] Preparation method one (prescriptions 7, 8, 10, 11): put lenvatinib mesylate, anhydrous calcium hydrogen phosphate, filler, and disintegrant into the fluidized bed and mix evenly with 5% poly The vitamin K30 ethanol solution is granulated, dried until the water content is less than 2%, and t...
Embodiment 3
[0049] The preparation of embodiment 3 lenvatinib mesylate capsules
[0050] Prescription 13:
[0051]
[0052] Preparation method: similar to Example 1. Anhydrous calcium hydrogen phosphate is micronized, and the particle size is about 400 mesh.
PUM
Property | Measurement | Unit |
---|---|---|
particle size (mesh) | aaaaa | aaaaa |
particle size (mesh) | aaaaa | aaaaa |
particle size (mesh) | aaaaa | aaaaa |
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com